Last reviewed · How we verify

NCT06172218

AM for Refractory Achilles Tendinopathy

Status unknown NA Last updated 15 December 2023
What this trial tests

NA trial testing Flo in Achilles Tendinopathy in 20 participants. Status unknown.

Timeline
22 November 2023
Primary endpoint
28 April 2024
28 June 2024

Quick facts

Lead sponsorNorth Park Podiatry
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment20
Start date22 November 2023
Primary completion28 April 2024
Estimated completion28 June 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

North Park Podiatry

Who can join

Adults 18 to 64, any sex, with Achilles Tendinopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate outcomes after use of micronized amniotic membrane to replace or supplement damaged or inadequate integumental tissue in patients with "chronic" insertional or non-insertional Achilles tendinopathy that remains refractory to standard care. Outcomes between a control and treatment group in this pilot study will be used to devise a multi-center study with larger sample size.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Achilles Tendinopathy

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06172218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing